文献速递肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

性别对尿路上皮癌与肾癌患者免疫治疗及抗体偶联药物肿瘤学结局的影响:系统综述与网络荟萃分析

Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2024-04-21

该系统综述与网络荟萃分析纳入18篇随机临床试验文章,评估免疫检查点抑制剂(ICI)与抗体偶联药物(ADC)在转移性肾细胞癌(RCC)和移行细胞癌(TCC)中疗效的性别差异。RCC辅助治疗中阿替利珠单抗对女性总生存有利(log OR [SE] = -0.57 ± 0.25,p = 0.024);TCC二线治疗中靶向Nectin-4的ADC对男性总生存有利(log OR [SE] = 0.65 ± 0.28,p = 0.02);其他结果无显著差异。

要点

  • RCC辅助阿替利珠单抗治疗中女性总生存优于男性(log OR [SE] = -0.57 ± 0.25,p = 0.024)。
  • TCC二线靶向Nectin-4的ADC治疗中男性总生存优于女性(log OR [SE] = 0.65 ± 0.28,p = 0.02)。
  • 其他ICI/ADC治疗的性别差异分析未显示显著结果。

核心结论

  • 网络荟萃分析揭示ICI和ADC在RCC与TCC治疗反应中存在性别特异性差异,为个性化癌症治疗和解决癌症诊疗与结局差异提供见解。

研究设计与样本

  • 系统综述与网络荟萃分析,系统检索截至2023年10月的英文随机临床试验文章,纳入18篇符合标准文章,评估ICI和ADC作为系统治疗(RCC一线及辅助治疗中的ICI;TCC一线及二线治疗中的ICI和ADC)的性别差异。
  • 主要目标为比较男性和女性之间ICI和ADC的总生存(OS);次要结局包括无进展生存、总缓解率、无病生存和無復發生存;通过比值比(OR)和置信区间与对照比较评估疗效,使用log OR构建频率学网络荟萃分析;该荟萃分析在PROSPERO注册(CRD42023468632)。

主要发现

  • RCC辅助治疗中,阿替利珠单抗对女性总生存有利(log OR [SE] = -0.57 ± 0.25,p = 0.024)。
  • TCC二线治疗中,靶向Nectin-4的ADC对男性总生存有利(log OR [SE] = 0.65 ± 0.28,p = 0.02)。
  • 其他分析未显示显著结果。

临床怎么用

  • 作者认为网络荟萃分析揭示的性别特异性差异可为个性化癌症治疗提供见解,并解决癌症诊疗与结局差异。
  • 作者指出迫切需要开展针对性别特异性癌症治疗的研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) herald a transformative era in metastatic renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) treatment, amid acknowledged sex-based disparities in these cancers. We conducted a systematic review and network meta-analysis (NMA) to identify sex-specific differences in the efficacy of ICI/ADC monotherapy or combination therapies for RCC and TCC survival, in metastatic and adjuvant settings. METHODS: A systematic search was conducted up to October 2023 for English articles on ICIs and ADCs as systemic therapies (ICIs in first-line and adjuvant treatment for RCC, ICIs and ADCs in first- and second-line treatment for TCC). Randomised clinical trials were considered. The primary objective was overall survival (OS) of ICIs and ADCs between males and females. The secondary outcomes included progression-free survival, overall response rate, disease-free survival, and recurrence-free survival. Treatment efficacy was evaluated by sex via odds ratios (ORs) and confidence intervals compared with controls. Log ORs were used for creating a frequentist NMA. This meta-analysis was registered on PROSPERO (CRD42023468632). KEY FINDINGS AND LIMITATIONS: Eighteen articles met the inclusion criteria. Females had an advantage for RCC-adjuvant treatment for atezolizumab (log OR [SE] = -0.57 ± 0.25, p = 0.024) in OS. Males showed a survival advantage in TCC second-line treatment for ADC-Nectin 4 (log OR [SE] = 0.65 ± 0.28, p = 0.02). No other significant results were shown. CONCLUSIONS AND CLINICAL IMPLICATIONS: The NMA revealed gender-specific variations in ICI and ADC responses for RCC and TCC, offering insights for personalised cancer care and addressing disparities in cancer care and outcomes. PATIENT SUMMARY: In this systematic review, we looked at the sex differences for metastatic renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) for antibody-drug conjugates and immune checkpoint inhibitors. In our analysis, female and male sex has better overall survival for adjuvant and second-line therapies for RCC and TCC, respectively. Urgent research on gender-specific cancer therapies is imperative.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Cerrato C, Crocerossa F, Marchioni M, et al. Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. Eur Urol Oncol. 2024. PMID: 38644155. doi:10.1016/j.euo.2024.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。